Cara Therapeutics, Inc. (NASDAQ:CARA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $14.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 11.11% from the company’s previous close.

According to Zacks, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. “

CARA has been the topic of a number of other reports. Vetr raised Cara Therapeutics from a “buy” rating to a “strong-buy” rating and set a $22.99 price target on the stock in a report on Tuesday, July 4th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price objective (down previously from $24.00) on shares of Cara Therapeutics in a research note on Friday, June 23rd. Cantor Fitzgerald reduced their price objective on Cara Therapeutics from $26.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, May 12th. BidaskClub downgraded Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a research note on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $25.50.

Cara Therapeutics (NASDAQ CARA) traded up 2.06% during trading on Wednesday, reaching $12.86. 1,229,355 shares of the company’s stock traded hands. Cara Therapeutics has a 52-week low of $5.27 and a 52-week high of $28.50. The company’s 50 day moving average is $14.06 and its 200-day moving average is $16.29. The stock’s market cap is $418.99 million.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.32. During the same period in the previous year, the firm earned ($0.48) earnings per share. The business’s revenue was down 100.0% on a year-over-year basis. On average, analysts anticipate that Cara Therapeutics will post ($1.78) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.watchlistnews.com/cara-therapeutics-inc-cara-rating-increased-to-buy-at-zacks-investment-research/1532410.html.

In other news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $15.00, for a total transaction of $45,000.00. Following the transaction, the vice president now owns 120,000 shares of the company’s stock, valued at approximately $1,800,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Dean Slagel sold 250,000 shares of the business’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $25.87, for a total value of $6,467,500.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 278,000 shares of company stock worth $6,888,750. Corporate insiders own 7.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CARA. Quantbot Technologies LP bought a new position in Cara Therapeutics during the first quarter valued at $124,000. Legal & General Group Plc increased its position in Cara Therapeutics by 10.4% in the second quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 678 shares in the last quarter. Fred Alger Management Inc. bought a new position in Cara Therapeutics during the second quarter valued at $123,000. UBS Group AG increased its position in Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new position in Cara Therapeutics during the second quarter valued at $171,000. 61.13% of the stock is currently owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.